<DOC>
	<DOC>NCT00145431</DOC>
	<brief_summary>The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.</brief_summary>
	<brief_title>Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.</brief_title>
	<detailed_description>For additional information please call: 1-800-718-1021</detailed_description>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type III</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Diagnosis of Familial Dysbetalipoproteinemia (Fredrickson Type III hyperlipoproteinemia) Women who are pregnant or lactating, or planning to become pregnant. Subjects with a clinically indicated need for statin (HMGCoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDLC and HDLC including fibrates and nicotinic acid Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMGCoA reductase inhibitors Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>